過活動膀胱を伴った前立腺肥大症症例に対するナフトピジルと塩酸タムスロシンとの治療効果の比較検討  [in Japanese] A COMPARATIVE STUDY ASSESSING CLINICAL EFFECTS OF NAFTOPIDIL AND TAMSULOSIN HYDROCHLORIDE ON BENIGN PROSTATIC HYPERPLASIA WITH OVERACTIVE BLADDER  [in Japanese]

(目的)蓄尿症状を主体とする排尿障害を有する前立腺肥大症(BPH)患者に対し二種のα1ブロッカーを投与し,その臨床効果を比較検討した.(対象と方法)対象は塩酸タムスロシン0.2mg/日またはナフトピジル50mg/日で8週間治療され,治療前後で自他覚所見を比較検討した過活動膀胱(OAB)症状を合併する121例のBPH患者である.(結果)ナフトピジルは国際前立腺症状スコア(IPSS)全ての項目において,塩酸タムスロシンは頻尿および腹圧排尿の項目以外全てにおいて有意に改善した.QOL indexは両群とも有意に改善した.他覚所見では両群とも最大尿流率において有意に改善したが,残尿量はどちらも有意な変化を認めなかった.二群間の有特注の比較でもナフトピジルの方が頻尿において有効であった.(結論)蓄尿症状の強いBPH患者においてはナフトピジルの方がより症状改善に寄与するものと考えられた.

(Purpose) We compared the efficacy of naftopidil with that of tamsulosin hydrochloride for 154 symptomatic benign prostatic hyperplasia (BPH) patients who also suffered from overactive bladder (OAB) symptoms. (Materials and methods) Naftopidil and tamsulosin hydrochloride were administered for eight weeks. The international prostate symptom score (IPSS), QOL index, maximum flow rate (Qmax), residual urine volume (RUV) and side effect profile were determined before the administration and after eight weeks of treatment. (Results) In the naftopidil group, seven parameters of IPSS and QOL index were improved significantly at the endpoint compared to the baseline. In the tamsulosin group, all parameters except frequency and straining were also improved. Both drugs improved the Qmax at the endpoint, too. The RUV did not change in both groups. Naftopidil was also superior to tamsulosin hydrochloride regarding general treatment outcome by the Japanese clinical guideline of urinary disturbance. (Conclusions) This study demonstrated that naftopidil was clinically efficacious in the treatment of BPH patients with 0 AB.